Cumberland Pharmaceuticals Inc (CPIX)

$1.5

+0.02

(+1.35%)

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $1.47
    $1.50
    $1.50
    downward going graph

    2.1%

    Downside

    Day's Volatility :2.1%

    Upside

    0.0%

    downward going graph
  • $1.38
    $2.36
    $1.50
    downward going graph

    8.0%

    Downside

    52 Weeks Volatility :41.53%

    Upside

    36.44%

    downward going graph

Returns

PeriodCumberland Pharmaceuticals IncIndex (Russel 2000)
3 Months
-9.76%
0.0%
6 Months
-20.43%
0.0%
1 Year
-1.99%
0.0%
3 Years
-54.6%
-19.9%

Highlights

Market Capitalization
21.0M
Book Value
$1.94
Earnings Per Share (EPS)
-0.59
PEG Ratio
0.0
Wall Street Target Price
8.5
Profit Margin
-21.68%
Operating Margin TTM
-22.0%
Return On Assets TTM
-4.79%
Return On Equity TTM
-26.58%
Revenue TTM
38.8M
Revenue Per Share TTM
2.73
Quarterly Revenue Growth YOY
-7.9%
Gross Profit TTM
32.9M
EBITDA
-1.7M
Diluted Eps TTM
-0.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Cumberland Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 466.67%

Current $1.50
Target $8.50

Company Financials

FY18Y/Y Change
Revenue
40.7M
↓ 0.99%
Net Income
-7.0M
↓ 12.73%
Net Profit Margin
-17.09%
↑ 2.3%
FY19Y/Y Change
Revenue
34.4M
↓ 15.59%
Net Income
-9.2M
↑ 32.29%
Net Profit Margin
-26.79%
↓ 9.7%
FY20Y/Y Change
Revenue
37.4M
↑ 8.88%
Net Income
-6.6M
↓ 28.07%
Net Profit Margin
-17.7%
↑ 9.09%
FY21Y/Y Change
Revenue
36.0M
↓ 3.89%
Net Income
-5.6M
↓ 15.53%
Net Profit Margin
-15.55%
↑ 2.15%
FY22Y/Y Change
Revenue
42.0M
↑ 16.75%
Net Income
-5.7M
↑ 0.95%
Net Profit Margin
-13.45%
↑ 2.1%
FY23Y/Y Change
Revenue
39.6M
↓ 5.85%
Net Income
-6.3M
↑ 11.14%
Net Profit Margin
-15.88%
↓ 2.43%
Q4 FY22Q/Q Change
Revenue
9.1M
↓ 20.06%
Net Income
-2.5M
↑ 481.18%
Net Profit Margin
-26.96%
↓ 23.25%
Q1 FY23Q/Q Change
Revenue
9.2M
↑ 1.11%
Net Income
192.2K
↓ 107.81%
Net Profit Margin
2.08%
↑ 29.04%
Q2 FY23Q/Q Change
Revenue
10.9M
↑ 18.04%
Net Income
872.2K
↑ 353.84%
Net Profit Margin
8.01%
↑ 5.93%
Q3 FY23Q/Q Change
Revenue
10.1M
↓ 7.37%
Net Income
-1.0M
↓ 220.3%
Net Profit Margin
-10.4%
↓ 18.41%
Q4 FY23Q/Q Change
Revenue
9.4M
↓ 7.27%
Net Income
-6.3M
↑ 499.55%
Net Profit Margin
-67.26%
↓ 56.86%
Q1 FY24Q/Q Change
Revenue
8.5M
↓ 9.15%
Net Income
-1.9M
↓ 69.06%
Net Profit Margin
-22.9%
↑ 44.36%
FY18Y/Y Change
Total Assets
112.7M
↑ 20.87%
Total Liabilities
57.1M
↑ 94.89%
FY19Y/Y Change
Total Assets
104.5M
↓ 7.23%
Total Liabilities
53.5M
↓ 6.41%
FY20Y/Y Change
Total Assets
96.5M
↓ 7.73%
Total Liabilities
49.6M
↓ 7.25%
FY21Y/Y Change
Total Assets
84.5M
↓ 12.44%
Total Liabilities
41.9M
↓ 15.59%
FY22Y/Y Change
Total Assets
92.9M
↑ 10.02%
Total Liabilities
57.0M
↑ 36.06%
FY23Y/Y Change
Total Assets
81.8M
↓ 12.0%
Total Liabilities
52.5M
↓ 7.79%
Q4 FY22Q/Q Change
Total Assets
92.9M
↑ 1.64%
Total Liabilities
57.0M
↑ 7.59%
Q1 FY23Q/Q Change
Total Assets
89.5M
↓ 3.72%
Total Liabilities
53.4M
↓ 6.2%
Q2 FY23Q/Q Change
Total Assets
89.4M
↓ 0.1%
Total Liabilities
52.5M
↓ 1.65%
Q3 FY23Q/Q Change
Total Assets
87.8M
↓ 1.82%
Total Liabilities
52.1M
↓ 0.84%
Q4 FY23Q/Q Change
Total Assets
81.8M
↓ 6.81%
Total Liabilities
52.5M
↑ 0.81%
Q1 FY24Q/Q Change
Total Assets
81.5M
↓ 0.33%
Total Liabilities
54.3M
↑ 3.43%
FY18Y/Y Change
Operating Cash Flow
3.1M
↓ 658.12%
Investing Cash Flow
-27.7M
↓ 391.45%
Financing Cash Flow
7.1M
↑ 266.5%
FY19Y/Y Change
Operating Cash Flow
3.1M
↓ 1.81%
Investing Cash Flow
2.3M
↓ 108.29%
Financing Cash Flow
-5.1M
↓ 171.17%
FY20Y/Y Change
Operating Cash Flow
5.4M
↑ 77.17%
Investing Cash Flow
-1.8M
↓ 176.5%
Financing Cash Flow
-7.1M
↑ 40.07%
FY21Y/Y Change
Operating Cash Flow
6.3M
↑ 17.13%
Investing Cash Flow
-501.9K
↓ 71.45%
Financing Cash Flow
-3.6M
↓ 50.06%
FY22Y/Y Change
Operating Cash Flow
8.5M
↑ 33.28%
Investing Cash Flow
-13.7M
↑ 2624.58%
Financing Cash Flow
-2.1M
↓ 41.98%
Q4 FY22Q/Q Change
Operating Cash Flow
2.8M
↓ 17.07%
Investing Cash Flow
-640.8K
↑ 465.81%
Financing Cash Flow
-2.8M
↑ 39.66%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.4M
↓ 149.87%
Investing Cash Flow
-96.8K
↓ 84.89%
Financing Cash Flow
-1.8M
↓ 36.02%
Q2 FY23Q/Q Change
Operating Cash Flow
5.2M
↓ 469.15%
Investing Cash Flow
-96.8K
↑ 0.0%
Financing Cash Flow
-3.3M
↑ 84.11%

Technicals Summary

Sell

Neutral

Buy

Cumberland Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
-1.33%
-20.43%
-1.99%
-54.6%
-74.08%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.73%
3.47%
45.25%
47.46%
69.5%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.24%
7.6%
2.41%
20.38%
20.38%
Zoetis Inc.
Zoetis Inc.
5.19%
-3.9%
-2.6%
-11.21%
55.91%
Viatris Inc.
Viatris Inc.
11.46%
-0.85%
9.89%
-16.16%
-28.58%
Catalent, Inc.
Catalent, Inc.
3.12%
18.35%
21.46%
-49.91%
6.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
NA
NA
0.0
0.0
-0.27
-0.05
NA
1.94
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.48
39.48
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.34
34.34
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
Sell
$21.0M
-74.08%
NA
-21.68%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
69.5%
39.48
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.38%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.5B
55.91%
34.34
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-28.58%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
6.12%
211.02
-28.44%

Insights on Cumberland Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 10.88M → 8.49M (in $), with an average decrease of 7.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.29M → -1.94M (in $), with an average increase of 223.2% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 47.1% return, outperforming this stock by 51.6%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 47.5% return, outperforming this stock by 102.1%

Institutional Holdings

  • Renaissance Technologies Corp

    3.82%
  • Vanguard Group Inc

    2.64%
  • Dimensional Fund Advisors, Inc.

    2.52%
  • Bridgeway Capital Management, LLC

    2.02%
  • Acadian Asset Management LLC

    1.33%
  • BlackRock Inc

    0.78%

Company Information

cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.

Organization
Cumberland Pharmaceuticals Inc
Employees
91
CEO
Mr. A. J. Kazimi MBA
Industry
Health Technology

FAQs